Cybin announces grant of u.s. patent covering deuterated tryptamines

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that the united states patent and trademark office (“uspto”) has granted u.s. patent 11,746,088, covering composition of matter for deuterated tryptamine compounds and pharmaceutical compositions thereof, with exclusivity unti.
CYBN Ratings Summary
CYBN Quant Ranking